In addition to the recently launched mTOR inhibitor everolimus, which is used for the treatment of a broad range of cancer types, a number of small molecule inhibitors of the PI3K/mTOR signaling pathway are currently in clinical development [7]–[10]. The gene discussed is PIK3CA; the disease is cancer.